Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BV100 (Rifabutin) in Hepatic Impairment
NCT05537142Phase 1Completed
- Sponsor
- BioVersys AG
- Start
- Sep 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rifabutin in Acinetobacter baumannii infection, sponsored by BioVersys AG. Primary endpoints: Pharmacokinetics of Rifabutin at 15 days and Single Dose Pharmacokinetic Profile of Rifabutin at 15 days. Started Sep 2022; status: completed.
02
Drugs
rifabutin
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT05537142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537142.